2Wozniak A J,Crowley J J,Balcezark S P,et al.Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC):A Southwest Oncology Group study[J].J Clin Oncol,1998,16(7):2459-2465. 被引量：1
3WHO handbook for reporting results of cancer treatment.Geneva(Switzerland):World Health Organaization Offset Publication No.48; 1997. 被引量：1
4Cancer Therapy Evaluation Program,Common Terminology Criteria for Adverse Events Version 3.0,DCDT,NCI,NIH.DHHS march 31,2003 (http:// ctep.cancer.gov). 被引量：1
5Hortobagyi G N,Hoimes F A.Single-agent paclitaxel for the treatment of breast cancer:an overview[J].Semin Oncol,1996,23(1Suppl):4. 被引量：1
6Sledge G W Jr,Loehrer P J Sr,Roth B J,et al.Cisplantin as first-line therapy for metastatic breast cancer[J].J Clin Oncol,1988,6:1811-1814. 被引量：1
7Ahn J H,Kim S B,Sohn H J,et al.Docetaxel and cisplantin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines[J].Breast,2005,14(4):304-309. 被引量：1
8Rosati.G,Riccardi F,Tucci A,et al.Phase Ⅱ study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy[J].Tumori,2000,86(3):207-210. 被引量：1
9Kamby C,Vestlev P M,Mouridsen H T.Site-specific effect of chemotherapy in patients with breast cancer[J].Acta Oncol,1992,31(2):225-229. 被引量：1
